Pale pink, oval-shaped extended-release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active
MFDS item code 202501913 · Approved 2025.07.25
Summary
Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000mg.
To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with the evening meal.
Take one tablet of this medicine 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily.
Patients taking this medicine 5/1000 mg extended-release tablet, 12.5/1000 mg extended-release tablet, 5/750mg extended-release tablet, or 12.5/750mg extended-release tablet should take 2 tablets together once daily.
To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually.
To maintain its extended-release properties, swallow this medicine whole without splitting, crushing, grinding, or chewing. This medicine may not dissolve completely and may be excreted in the feces.
It is not known whether the material excreted in the feces contains the active ingredient of the medicine. If a patient repeatedly reports finding this medicine in their feces, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General precautions).
⦁ For patients who are unable to achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose when taking this medicine is empagliflozin 10 mg plus the patient's current metformin dose. If empagliflozin 10 mg is well tolerated but additional glycemic control is needed, the dose of empagliflozin may be increased to 25 mg.
⦁ Patients switching from concomitant empagliflozin and metformin therapy to this medicine should receive their previous doses of empagliflozin and metformin.
When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose appropriately adjusted.
Special populations
Renal impairment
Because dosage adjustment is required according to renal function, assessment of renal function is recommended before starting this medicine and periodically during treatment.
No dosage adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧60 mL/min/1.73 m2].
In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and have no other condition that may increase the risk of lactic acidosis, this medicine may be used with adjustment of the metformin hydrochloride dose as follows.
- The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg.
If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to below 45 ml/min/1.73m2, discontinue this medicine immediately.
Older adults
In patients 75 years of age and older, consider renal function and the risk of volume depletion.
Improvement of glycemic control in adults with type 2 diabetes mellitus
Abnormal blood sugar control in adult type 2 diabetes patients
cardiovascular disease
cardiovascular events
View approved original textHide original text
This medication is suitable for adults with type 2 diabetes who have difficulty controlling blood sugar, when used in conjunction with diet and exercise. In particular, it helps improve blood sugar levels by combining empagliflozin and metformin. Furthermore, caution is required for adult type 2 diabetes patients with cardiovascular disease regarding the risk of cardiovascular events. It is important to consult with a healthcare professional before use, and this medication is effectively used for controlling blood sugar and preventing related complications.
How to take
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000mg.
To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with the evening meal.
Take one tablet of this medicine 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily.
Patients taking this medicine 5/1000 mg extended-release tablet, 12.5/1000 mg extended-release tablet, 5/750mg extended-release tablet, or 12.5/750mg extended-release tablet should take 2 tablets together once daily.
To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually.
To maintain its extended-release properties, swallow this medicine whole without splitting, crushing, grinding, or chewing. This medicine may not dissolve completely and may be excreted in the feces.
It is not known whether the material excreted in the feces contains the active ingredient of the medicine. If a patient repeatedly reports finding this medicine in their feces, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General precautions).
⦁ For patients who are unable to achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose when taking this medicine is empagliflozin 10 mg plus the patient's current metformin dose. If empagliflozin 10 mg is well tolerated but additional glycemic control is needed, the dose of empagliflozin may be increased to 25 mg.
⦁ Patients switching from concomitant empagliflozin and metformin therapy to this medicine should receive their previous doses of empagliflozin and metformin.
When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose appropriately adjusted.
Special populations
Renal impairment
Because dosage adjustment is required according to renal function, assessment of renal function is recommended before starting this medicine and periodically during treatment.
No dosage adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧60 mL/min/1.73 m2].
In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and have no other condition that may increase the risk of lactic acidosis, this medicine may be used with adjustment of the metformin hydrochloride dose as follows.
- The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg.
If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to below 45 ml/min/1.73m2, discontinue this medicine immediately.
Older adults
In patients 75 years of age and older, consider renal function and the risk of volume depletion.
Precautions
This medication is used for the treatment of diabetes and contains two components that help control blood sugar.
It is essential to verify normal kidney function before taking this medication, and it should not be administered to patients with impaired kidney function.
This drug should not be used in patients with serious illnesses such as severe renal impairment, acute heart failure, acute myocardial infarction, or severe infections.
Additionally, individuals allergic to any components of this medication should not take it.
This medication can cause a rare but very serious side effect known as lactic acidosis, so special caution is required in cases of dehydration, hypoxia, or liver dysfunction.
When used in combination with other diabetes medications, hypoglycemia may occur, so dosage adjustments may be necessary when used together with insulin or sulfonylureas.
This drug may increase the risk of genital and urinary tract infections, so consult a doctor immediately if any infection symptoms occur.
Regular blood tests are important to monitor kidney function and vitamin B12 levels during treatment.
It is advisable for pregnant women, women of childbearing potential, or nursing mothers to avoid using this medication.
Elderly patients or those at risk of fluid loss should be cautious about dehydration and low blood pressure and may need to temporarily discontinue the drug if necessary.
Patients scheduled for surgery should stop taking this medication 48 hours prior to surgery and resume only after confirming normal kidney function post-surgery.
This drug should be swallowed whole and not chewed or crushed, and its coating may appear in stools, which is normal.
Overdose can cause severe side effects like lactic acidosis, so immediate medical attention is required for any unusual symptoms.
It is advisable to avoid excessive alcohol consumption while taking this medication, and any changes in symptoms or adverse reactions should be reported to a healthcare professional immediately.
Side effects
Hypoglycemia
urinary tract infection
genital infection
increased urination
decreased and deficiency of vitamin B12
ketoacidosis
lactic acidosis
decreased fluid volume
nausea
vomiting
Show 147 moreCollapse
diarrhea
abdominal pain
loss of appetite
constipation
abnormal liver function tests
hepatitis
dysgeusia
pruritus
rash
urticaria
erythema
angioedema
difficulty urinating
interstitial nephritis
thirst
elevated serum lipids
increased serum creatinine
decreased glomerular filtration rate
increased hematocrit
perineal necrosis
liver damage
urosepsis
pyelonephritis
rash
urticaria
angioedema
perineal necrosis
chronic gastritis
various neurological disorders
cerebral infarction
soft tissue infection
pneumonia
ankle fracture
epicondylitis
facial bone fracture
musculoskeletal pain
myocardial infarction
pancreatic adenocarcinoma
diarrhea
nausea
gastric ulcer
colitis
vomiting
ischemic colitis
gastrointestinal bleeding
appendiceal abscess
appendicitis
chronic otitis media
peritonsillar abscess
pulmonary tuberculosis
acute pyelonephritis
sepsis
subcutaneous abscess
adnexal-ovarian abscess
vestibular neuritis
headache
cerebral infarction
intracranial aneurysm
fever
vascular stent stenosis
vascular stent thrombosis
elevated alanine aminotransferase
elevated aspartate aminotransferase
ureteral stones
acute kidney injury
cervicitis
hyperglycemia
hyponatremia
insomnia
dizziness
vulvar pruritus
genital pruritus
dyslipidemia
hyperglycemia
dermoid cyst
seborrheic dermatitis
atopic dermatitis
diabetic foot
nummular eczema
heat rash
sebaceous gland hyperplasia
lumbar spinal stenosis
myalgia
limb pain
musculoskeletal chest pain
arthralgia
cervical stenosis
fibromyalgia
flank pain
fracture pain
muscle weakness
osteoarthritis
osteoporosis
rotator cuff syndrome
astigmatism
cataract
allergic conjunctivitis
blurred vision
corneal erosion
glaucoma
macular fibrosis
ocular discomfort
conjunctival congestion
pathologic myopia
retinal detachment
retinal crystal formation
retinal vein occlusion
retinal detachment with tears
eyelid swelling
visual impairment
vitreous floaters
vitreous hemorrhage
epistaxis
asthma
exertional dyspnea
wet cough
allergic rhinitis
residual phlegm
cough
epistaxis
allergic rhinitis
skin laceration
rib fracture
long ligament syndrome
angina
palpitations
Prinzmetal angina
coronary artery disease
tachycardia
arteriosclerosis
deep vein thrombosis
diabetic vascular complications
peripheral arterial occlusive disease
anxiety
depression
sleep disorders
acute cholecystitis
autoimmune hepatitis
cholelithiasis
hepatitis
otalgia
postural dizziness
dizziness
anemia
lymphadenopathy
hypothyroidism
thyroid nodule
Not everyone experiences these, and they can vary from person to person.
Storage
This medication should be stored in a tightly sealed container, protected from air and moisture, and maintained at room temperature between 1 to 30 degrees Celsius. Proper storage will safely preserve the medication's effectiveness.
Appearance and packaging
Appearance
Pale pink, oval-shaped extended-release film-coated tablet
Package unit
30 tablets/bottle
Same-ingredient medicines
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.